SEC Form 4 · accession 0000899243-16-021116
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn E Falberg
Director
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | holding | — | — | — | 94,894 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(right to buy)F2 | $15.40 | May 25, 2016 | A | 19,755 | A | — | May 25, 2026 | Common Stock | 19,755 | 19,755 | D |
Explanation of responses
- F1A portion of these shares is subject to a right of repurchase held by the Issuer.
- F2The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2017 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.